ADARx Pharmaceuticals tech chief holds 2.51M shares
Some later option grants vest in quarterly installments subject to continued service, while other options are fully vested and exercisable.
Rhea-AI Filing Summary
ADARx Pharmaceuticals, Inc. Chief Technology Officer Zhu Rui reported 2,511,943 directly held common shares and directly held employee stock options for common stock. The options have exercise prices of $0.24, $0.56, $2.29, $3.26, $5.84, $6.31 or $7.05 per share, with expiration dates from August 19, 2030, through January 27, 2036. Footnotes describe some options as fully vested and exercisable and later grants as vesting quarterly subject to continued service.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Zhu Rui (NMN)
Role
Chief Technology Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F6 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F7 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F8 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F9 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 1,277,859 contracts (Direct);
Common Stock — 2,511,943 shares (Direct)
Footnotes (9)
- F1. Granted to the Reporting Person on August 20, 2020. The shares subject to the option are fully vested and exercisable.
- F2. Granted to the Reporting Person on December 7, 2020. The shares subject to the option are fully vested and exercisable.
- F3. Granted to the Reporting Person on March 19, 2021. The shares subject to the option are fully vested and exercisable.
- F4. Granted to the Reporting Person on May 21, 2021. The shares subject to the option are fully vested and exercisable.
- F5. Granted to the Reporting Person on February 23, 2022. The shares subject to the option are fully vested and exercisable.
- F6. Granted to the Reporting Person on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 1, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F7. Granted to the Reporting Person on January 17, 2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F8. Granted to the Reporting Person on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F9. Granted to the Reporting Person on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Key Figures
Direct common shares: 2,511,943 shares
Underlying common shares subject to options: 501,996 shares
Underlying common shares subject to options: 140,305 shares
+5 more
8 metrics
Direct common shares
2,511,943 shares
Common Stock held directly
Underlying common shares subject to options
501,996 shares
$0.24 exercise price; expires August 19, 2030
Underlying common shares subject to options
140,305 shares
$0.24 exercise price; expires December 6, 2030
Underlying common shares subject to options
362,453 shares
$0.56 exercise price; expires May 20, 2031
Underlying common shares subject to options
34,138 shares
$2.29 exercise price; expires February 22, 2032
Underlying common shares subject to options
42,673 shares
$3.26 exercise price; expires February 25, 2033
Underlying common shares subject to options
42,673 shares
$7.05 exercise price; expires February 11, 2035
Underlying common shares subject to options
68,276 shares
$6.31 exercise price; expires January 27, 2036
Key Terms
fully vested and exercisable, equal quarterly installments, continued service to the Issuer
3 terms
fully vested and exercisable technical
"The shares subject to the option are fully vested and exercisable."
equal quarterly installments technical
"remaining shares vest and become exercisable in equal quarterly installments"
continued service to the Issuer technical
"subject to the Reporting Person's continued service to the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How do Zhu Rui's ADRX stock options vest?
For grants made February 26, 2023, January 17, 2024, February 12, 2025, and January 28, 2026, one quarter of the shares vested or will vest on January 1, 2024, January 1, 2025, January 1, 2026, and January 1, 2027, respectively. The remaining shares vest in equal quarterly installments over three years, subject to continued service on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
